Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)
In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Hold rating on Fate Therapeutics (FATE – Research Report), with ...
Marvell price target lowered to $115 from $130 at Stifel
Stifel analyst Tore Svanberg lowered the firm’s price target on Marvell (MRVL) to $115 from $130 and keeps a Buy rating on the shares. The firm ...